Format

Send to

Choose Destination
Methods Mol Biol. 2009;520:11-9. doi: 10.1007/978-1-60327-811-9_2.

Autoantibodies against cancer antigens.

Author information

1
Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Abstract

With the identification of tumor antigens, the host immune response to various types of cancers can now be studied with a high degree of specificity in large cohorts of patients, in the hope of correlating immunity with clinical events and defining immunotherapeutic strategies. Several antigens, such as NY-ESO-1, p53, or SOX2, have attracted attention because of their frequent spontaneous immunogenicity in cancer patients, notably in their ability to induce humoral responses. We describe in this chapter a simple implementation of a serological monitoring platform for autoantibody measurement in cancer patients, from production of recombinant antigens to ELISA testing and interpretation.

PMID:
19381944
DOI:
10.1007/978-1-60327-811-9_2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center